Skip to content

Investor Relations / Press Releases

Press Releases

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary Additional Formats
Toggle Summary Amarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations
Record Revenue of $181.1 Million and $ 53.9 Million for Full Year and Fourth Quarter 2017   REDUCE-IT Cardiovascular Outcomes Study Remains on Schedule to Report Top-Line Results Before the End of Q3 2018 Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J.
View HTML
Toggle Summary Amarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018
BEDMINSTER, N.J. and DUBLIN, Ireland , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with
View HTML
Toggle Summary Amarin Prices Public Offering of American Depositary Shares
BEDMINSTER, N.J. and DUBLIN, Ireland , Jan. 30, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") for gross proceeds of approximately $70.0 million , before deducting the
View HTML
Toggle Summary Amarin Announces Proposed Public Offering of American Depositary Shares
BEDMINSTER, N.J. , and DUBLIN, Ireland , Jan. 29, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a registered underwritten public offering of its American Depositary Shares.  All of the shares in the proposed offering are to be sold by Amarin.  The offering is subject
View HTML
Toggle Summary Amarin's REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events
On Track for Patient Final Study Visits to Commence in March 2018
View HTML
Toggle Summary Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland China
BEDMINSTER, N.J. and DUBLIN, Ireland , Jan. 17, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics, today announced that a clinical trial of Vascepa® (icosapent ethyl) capsules in a patient
View HTML
Toggle Summary Amarin Provides Preliminary 2017 Results and Provides 2018 Outlook
Unaudited Full-Year 2017 Net Product Revenue Estimated Between $177 and $180 Million , Exceeding Upper End of Previously Provided Guidance, with Fourth Quarter Estimate Between $51 and $54 Million Anticipate 2018 Net Product Revenue Growth of Approximately $50 Million or $230 Million for Full-Year
View HTML
Toggle Summary Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018
On-Track to Report Clinical Results for this Potential Landmark Study Before the End of Q3 2018
View HTML
Toggle Summary Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco
BEDMINSTER, N.J. , and DUBLIN, Ireland , Dec. 18, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
View HTML
Toggle Summary Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk
High Triglyceride Levels Associated with 30% Increased Risk of Myocardial Infarction & Coronary Revascularization and 13% Overall Increase in Major Adverse Cardiovascular Events
View HTML
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation